Biohaven’s Migraine Empire Expands As Zavegepant Conquers Phase III

Second Drug Is Market’s First Intranasal CGRP Inhibitor

 
• By Mandy Jackson
Young female student with headache
Ultra-rapid onset in as soon as 15 minutes could keep migraine patients from leaving school or work • Source: Alamy

More from Clinical Trials

More from R&D